• Natural Product Inhibitors Targeting SARS-CoV-2 NSP15: Insig

  2026-07-27

  This article reviews the structure-based virtual screening of natural products targeting the NSP15 endoribonuclease of SARS-CoV-2, highlighting the identification of thymopentin and oleuropein as potent and stable inhibitors. The findings provide critical insight into antiviral drug discovery and underscore the potential for repurposing bioactive compounds in virology research.

• Amplifying Discovery: TSA Fluorescence in Brain Atlas Scienc

  2026-07-27

  Translational research demands precision tools to visualize cellular heterogeneity at the molecular level. This article explores how the Fluorescein TSA Fluorescence System Kit enables ultrasensitive detection of low-abundance biomolecules, turning the tide in neuroscience research. By bridging mechanistic insight, strategic workflow optimization, and the latest advances in astrocyte transcriptomics, we offer actionable guidance for researchers seeking to unlock cellular complexity and drive next-generation discoveries.

• Annexin V-Cy5/DAPI Apoptosis Kit: Precision in Cell Death As

  2026-07-26

  The Annexin V-Cy5/DAPI Apoptosis Kit stands out as a rapid, dual-parameter solution for distinguishing apoptosis and necrosis in translational leukemia research and beyond. Its streamlined workflow and robust sensitivity accelerate mechanistic discovery, as exemplified in recent P2RX1-driven apoptosis studies.

• BAY-826: Potent Small Molecule Inhibitor for Retinal Studies

  2026-07-25

  BAY-826 is a potent small molecule inhibitor widely used to dissect angiopoietin and pigment epithelium-derived factor (PEDF) signaling in retinal neuron survival research. Its nanomolar IC50 and high selectivity provide precise modulation of neurovascular pathways implicated in hypoxic and degenerative retinal diseases.

• 3X (DYKDDDDK) Peptide: Redefining Translational Protein Scie

  2026-07-24

  This thought-leadership article explores how the 3X (DYKDDDDK) Peptide is reshaping the landscape of recombinant protein research, bridging mechanistic insight with workflow strategy for translational scientists. Drawing on recent advances in mitochondrial lipid transfer biology, including the structural and functional elucidation of TANGO2 as an acyl-CoA binding protein, we examine the peptide’s impact on experimental rigor, reproducibility, and clinical translation. With comparative analysis, protocol guidance, and a forward-looking outlook, we position APExBIO’s 3X FLAG peptide as an indispensable tool for next-generation affinity purification and protein detection in complex biomedical workflows.

• Gut-Brain Cholinergic Pathways in Microbiota-Mediated Seizur

  2026-07-24

  Jia et al. elucidate a gut-brain cholinergic signaling pathway by which Bacteroides fragilis suppresses seizures, integrating mouse models and a pediatric clinical trial. Their findings establish a mechanistic link between microbiota composition, cholinergic neurotransmission, and refractory epilepsy, suggesting new strategies for neuropsychiatric disorder research.

• Phosbind Acrylamide: Advancing Translational Phosphorylation

  2026-07-23

  Explore how Phos binding reagent (Phosbind) acrylamide is reshaping translational protein phosphorylation analysis. This article integrates mechanistic insights, recent plant signaling discoveries, and strategic guidance for researchers, emphasizing the unique advantages of APExBIO's Phosbind Acrylamide over traditional phospho-antibody methods.

• Synthesis of Deuterium-Labeled Degarelix: Enabling PK Studie

  2026-07-23

  This study details an efficient multi-step synthesis of deuterium-labeled degarelix acetate, providing a robust internal standard for pharmacokinetic and metabolism investigations of GnRH antagonists. The protocol supports precise molecular tracing, facilitating advanced research in androgen-related disease therapeutics.

• Solving Cell Assay Challenges with T0070907: Precision PPARγ

  2026-07-22

  This article explores how T0070907 (SKU A4301), a potent and selective PPARγ antagonist, addresses common challenges in cell viability, proliferation, and cytotoxicity assays. Grounded in recent literature and real-world laboratory scenarios, the discussion emphasizes experimental reproducibility, mechanistic clarity, and vendor reliability for biomedical researchers seeking robust tools for PPARγ pathway interrogation.

• Patient-Derived Gastric Cancer Assembloids Advance Drug Test

  2026-07-22

  This study introduces a patient-derived gastric cancer assembloid model that integrates matched tumor organoids with stromal cell subpopulations, improving the physiological relevance of preclinical drug testing. The findings reveal how stromal components critically modulate gene expression and drug response, providing a robust platform to investigate resistance mechanisms and personalize therapeutic strategies.

• Novel Allosteric PDK4 Inhibitors for Metabolic Disease Thera

  2026-07-21

  This article examines a recent study that identified a new class of allosteric pyruvate dehydrogenase kinase 4 (PDK4) inhibitors, notably compound 8c, as promising candidates for oral treatment of metabolic diseases. The work demonstrates significant advances in inhibitor design, metabolic stability, and translational disease models, with implications for future drug discovery and mechanistic metabolic research.

• (R)-MG132: Precision Controls for Proteasome Research in Can

  2026-07-21

  (R)-MG132, the stereochemically inactive MG-132 enantiomer, is redefining negative control standards in proteasome inhibition studies. This thought-leadership article explores the mechanistic necessity and translational impact of using (R)-MG132 in cancer metabolism research—especially in light of discoveries linking HNRNPU K181 lactylation to metabolic rewiring in cervical cancer. We bridge the gap between rigorous experimental design and strategic innovation, guiding translational researchers in leveraging (R)-MG132 for unambiguous proteasome inhibition validation.

• Golgi-Tracker Green: Accelerating Live-Cell Golgi Imaging Wo

  2026-07-20

  Golgi-Tracker Green unlocks high-specificity, photostable visualization of the Golgi apparatus in live cells, surpassing conventional probes for both lipid transport and sphingolipid metabolism studies. Its workflow-friendly design and robust performance make it indispensable for translational research demanding reproducible, high-contrast organelle imaging.

• Mitomycin C: Antitumor Antibiotic Solutions for Cancer Resea

  2026-07-20

  Mitomycin C stands out as an antitumor antibiotic, uniquely enabling robust DNA replication inhibition and sensitization of cancer cells to apoptosis in translational research. This article details actionable protocols, troubleshooting insights, and advanced applications, empowering oncology labs to optimize workflows with APExBIO's Mitomycin C.

• Patient-Derived Gastric Cancer Assembloids Enhance Drug Mode

  2026-07-19

  This study pioneers a patient-specific gastric cancer assembloid model that incorporates matched tumor organoids and diverse stromal cell subpopulations, better recapitulating the in vivo tumor microenvironment. The model reveals how stromal diversity influences drug response and resistance, providing a more predictive platform for preclinical oncology research and personalized therapy optimization.

452 records 10/31 page Previous Next First page 上5页 678910 下5页 Last page